Speaker Profile
Ph.D., VP Head of Research, Tune Tx
Biography
Dr. Blythe Sather, a leader at Tune Therapeutics, has focused her career on genetic and epigenetic modifications for disease treatment. She earned her Ph.D. in Immunology from the University of Washington, studying regulatory T cells, and conducted postdoctoral research on lentiviral gene therapies at Seattle Childrens Research Institute. At Lyell Immunopharma, Dr. Sather developed CAR and TCR products for solid tumors as Senior Director. At Juno Therapeutics, she helped build the CAR T cell platform and led the multiple myeloma CAR T cell program, collaborating with Editas Medicine on CRISPR-mediated gene editing. Now at Tune, she develops technologies to regulate gene expression, aiming to create therapies for viruses, cancer, and rare genetic disorders.
Session Abstract – PMWC 2025 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Morten Sogaard, Astellas Gene Therapies
- PMWC 2025 Award Ceremony
Pioneer Honoree: James M. Wilson, University of Pennsylvania
Luminary Honoree: Carolyn Bertozzi, Stanford
- Keynote: Bioorthogonal Chemistry, from Basic Science to Clinical Translation
- Carolyn Bertozzi, Stanford
- Keynote: The Promise of Genetic Medicines Unless You're Too Poor or Too Rare
- James M. Wilson, University of Pennsylvania
- Reimbursement for Genetic Medicines in Rare Diseases
Chair:
- Erin Satterwhite, Optum Specialty Pharmacy
- Next-Generation Delivery Systems for Gene Therapies (PANEL)
Chair: Morten Sogaard, Astellas
- Mathieu Nonnenmacher, Voyager Therapeutics
- Kevin Friedman, Kelonia Therapeutics
- Kunwoo Lee, GenEdit
- Haig Aghajanian, Capstan Therapeutics
- James M. Wilson, University of Pennsylvania
- Beyond the Genome: Harnessing Epigenetics in Rare Disease Treatment (PANEL)
Chair: Charles Gersbach, Duke
- Prashant Mali, UCSD
- Nadav Ahituv, UCSF
- Blythe Sather, Tune Therapeutics
- Fyodor D Urnov, Berkely University
- Navigating the Regulatory Landscape for Gene and Cell Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Courtney Silverthorn, Bespoke Gene Therapy Consortium (BGTC)
- Peter Marks, FDA
- Ben Dewees, Kyverna Therapeutics
- AI-driven Improvements in Gene and Cell Therapy (PANEL)
Chair: Morten Sogaard, Astellas
- Francois Vigneault, Shape Therapeutics
- John Androsavich, Ginkgo Bioworks
- Yogev Debbi, mana.bio
